Download PDF
Thromb Haemost 1987; 58(04): 1094
DOI: 10.1055/s-0038-1646063
Letter to the Editor
Schattauer GmbH Stuttgart

Different Prevalence of Thromboembolism in the Subtypes of Congenital Antithrombin III Deficiency:Review of 404 Cases

Guido Finazzi
Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
,
Roberto Caccia
Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
,
Tiziano Barbui
Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
› Author Affiliations
Further Information

Publication History

Received 19 May 1987

Accepted after revision 24 August 1987

Publication Date:
29 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Sas G. Hereditary antithrombin III deficiency: biochemical aspects. Haematologia (Budap.) 1984; 17: 81-86
    PubMedGoogle Scholar
  • 2 Mannucci PM, Tripodi A, Mari D. Congenital deficiencies of anticoagulant piuteins (Antitlnombin HI and Protein C). Ilaeniatulogica 1984; 69: 730-746
    PubMedGoogle Scholar
  • 3 Thaler F, Lechner K. Antithrombin TIT deficiency and thromboembolism. Clinics in Haematology 1981; 10 (02) 369-390
    PubMedGoogle Scholar
  • 4 Penner JA, Hassouna H, Hunter MJ, Chockley M. A clinically silent antithrombin III defect in an Ann Arbor family. Thromb Haemostas 1979; 43: 186 (Abstr)
    PubMedGoogle Scholar
  • 5 Tran TH, Ronnameaux H, Bondeli C, Honkanen H, Marbet GA, Duckert F. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemostas 1980; 44: 87-91
    PubMedGoogle Scholar
  • 6 Wolf M, Boyer C, Lavergne M, Larrieu MJ. A new familial variant of antithrombin III: “Antithrombin III Paris”. Br J Haematol 1982; 51: 285-295
    CrossrefPubMedGoogle Scholar
  • 7 Girolami A, Pengo V, Cappellato G, Vianello C, Procidano M, Cartei C. Antithrombin III Padua: a “new” congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. Folia Haematol 1983; 110: 98-111
    PubMedGoogle Scholar
  • 8 Girolami A, Fabris F, Cappellato G, Sainati L, Boeri G. Antithrombin III (AT III) Padua2: a “new” congenital abnormality with defective heparin cofactor activities but no thrombotic disease. Blut 1983; 47: 93-103
    CrossrefPubMedGoogle Scholar
  • 9 Fischer AM, Gazengel C, Dautzenberg MD, Benhammo J, Béguin S, Vergoz D. A new case of abnormal antithrombin III (AT III): biological characteristics and thromboembolic accidents management. Thromb Haemostas 1983; 50: 358 (Abstr)
    PubMedGoogle Scholar
  • 10 Sakuragawa N, Takahashi K, Koide T. Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Thromb Res 1983; 31: 305-317
    CrossrefPubMedGoogle Scholar
  • 11 Chasse JF, Esnard F, Guitton JD, Mouray H, Perigois F, Fauconneau G, Gauthier F. An abnormal plasma antithrombin with no apparent affinity for heparin. Thromb Res 1984; 34: 297-302
    CrossrefPubMedGoogle Scholar
  • 12 Boyer C, Wolf M, Vedrenne J, Meyer D, Larrieu MJ. Homozygous variant of antithrombin III: AT III Fontainebleau. Thromb Haemostas 1986; 56: 18-22
    PubMedGoogle Scholar
  • 13 Fischer AM, Cornu P, Sternberg C, Mériane F, Dautzenberg MD, Chafa O, Beguin S, Desnos M. Antithrombin III Alger: a new homozygous AT III variant. Thromb Haemostas 1986; 55: 218-221
    PubMedGoogle Scholar
  • 14 Girolami A. The incidence of thrombotic manifestations in AT III abnormalities. Thromb Haemostas 1987; 57: 123
    PubMedGoogle Scholar